Neurobion Advance 100 mg + 50 mg + 1 mg Tabletki powlekane Polska - polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

neurobion advance 100 mg + 50 mg + 1 mg tabletki powlekane

p&g health germany gmbh - thiamini nitras + pyridoxini hydrochloridum + cyanocobalaminum - tabletki powlekane - 100 mg + 50 mg + 1 mg

Zoledronic acid Teva Pharma Unia Europejska - polski - EMA (European Medicines Agency)

zoledronic acid teva pharma

teva b.v. - kwas zoledronowy - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - leki stosowane w leczeniu chorób kości - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. leczenie choroby pageta kości u dorosłych.

Teriparatide Sun Unia Europejska - polski - EMA (European Medicines Agency)

teriparatide sun

sun pharmaceutical industries europe b.v. - teryparatyd - osteoporosis; osteoporosis, postmenopausal - wapń homeostaza - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Kauliv Unia Europejska - polski - EMA (European Medicines Agency)

kauliv

strides pharma (cyprus) limited - teryparatyd - osteoporosis; osteoporosis, postmenopausal - wapń homeostaza - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.